6 research outputs found
Covalent cell surface conjugation of nanoparticles by a combination of metabolic labeling and click chemistry
Conjugation of nanoparticles (NP) to the surface of living cells is of interest in the context of exploiting the tissue homing properties of ex vivo engineered T cells for tumor-targeted delivery of drugs loaded into NP. Cell surface conjugation requires either a covalent or non-covalent reaction. Non-covalent conjugation with ligand-decorated NP (LNP) is challenging and involves a dynamic equilibrium between the bound and unbound state. Covalent NP conjugation results in a permanently bound state of NP, but the current routes for cell surface conjugation face slow reaction kinetics and random conjugation to proteins in the glycocalyx. To address the unmet need for alternative bioorthogonal strategies that allow for efficient covalent cell surface conjugation, we developed a 2-step click conjugation sequence in which cells are first metabolically labeled with azides followed by reaction with sulfo-6-methyl-tetrazine-dibenzyl cyclooctyne (Tz-DBCO) by SPAAC, and subsequent IEDDA with trans-cyclooctene (TCO) functionalized NP. In contrast to using only metabolic azide labeling and subsequent conjugation of DBCO-NP, our 2-step method yields a highly specific cell surface conjugation of LNP, with very low non-specific background binding
Lipid-polyglutamate nanoparticle vaccine platform
Peptide-based subunit vaccines are attractive in view of personalized cancer vaccination with neo-antigens, as well as for the design of the newest generation of vaccines against infectious diseases. Key to mounting robust antigen-specific immunity is delivery of antigen to antigen-presenting (innate immune) cells in lymphoid tissue with concomitant innate immune activation to promote antigen presentation to T cells and to shape the amplitude and nature of the immune response. Nanoparticles that co-deliver both peptide antigen and molecular adjuvants are well suited for this task. However, in the context of peptide-based antigen, an unmet need exists for a generic strategy that allows for co-encapsulation of peptide and molecular adjuvants due to the stark variation in physicochemical properties based on the amino acid sequence of the peptide. These properties also strongly differ from those of many molecular adjuvants. Here, we devise a lipid nanoparticle (LNP) platform that addresses these issues. Key in our concept is poly(L-glutamic acid) (PGA), which serves as a hydrophilic backbone for conjugation of, respectively, peptide antigen (Ag) and an imidazoquinoline (IMDQ) TLR7/8 agonist as a molecular adjuvant. Making use of the PGA's polyanionic nature, we condensate PGA-Ag and PGA-IMDQ into LNP by electrostatic interaction with an ionizable lipid. We show in vitro and in vivo in mouse models that LNP encapsulation favors uptake by innate immune cells in lymphoid tissue and promotes the induction of Ag-specific T cells responses both after subcutaneous and intravenous administration
LXR signaling controls homeostatic dendritic cell maturation
Dendritic cells (DCs) mature in an immunogenic or tolerogenic manner depending on the context
in which an antigen is perceived, preserving the balance between immunity and tolerance. Whereas
the pathways driving immunogenic maturation in response to infectious insults are well-characterized,
the signals that drive tolerogenic maturation during homeostasis are still poorly
understood. We found that the engulfment of apoptotic cells triggered homeostatic maturation of
conventional cDC1s within the spleen. This maturation process could be mimicked by engulfment
of empty, non-adjuvanted lipid nanoparticles (LNPs), was marked by intracellular accumulation
of cholesterol, and highly unique to type 1 DCs. Engulfment of either apoptotic cells or cholesterol-rich
LNPs led to activation of the LXR pathway, which promotes the efflux of cellular cholesterol,
and repressed genes associated with immunogenic maturation. In contrast, simultaneous
engagement of TLR3 to mimic viral infection via administration of poly(I:C)-adjuvanted LNPs
repressed the LXR pathway, thus delaying cellular cholesterol efflux and inducing genes that
promote T cell-mediated immunity. These data demonstrate that conserved cellular cholesterol
efflux pathways are differentially regulated in in tolerogenic versus immunogenic cDC1s and
suggest that administration of non-adjuvanted cholesterol-rich LNPs may be an approach for
inducing tolerogenic DC maturation